[Code of Federal Regulations] [Title 21, Volume 7] [Revised as of April 1, 2007] From the U.S. Government Printing Office via GPO Access [CITE: 21CFR610.41] [Page 80] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) PART 610_GENERAL BIOLOGICAL PRODUCTS STANDARDS--Table of Contents Subpart E_Testing Requirements for Communicable Disease Agents Sec. 610.41 Donor deferral. (a) You, an establishment that collects human blood or blood components, must defer donors testing reactive by a screening test for evidence of infection due to a communicable disease agent(s) listed in Sec. 610.40(a) or reactive for a serological test for syphilis under Sec. 610.40(i), from future donations of human blood and blood components, except: (1) You are not required to defer a donor who tests reactive for anti-HBc or anti-HTLV, types I or II, on only one occasion. When a supplemental (additional, more specific) test for anti-HBc or anti-HTLV, types I and II, has been approved for use under Sec. 610.40(e) by FDA, such a donor must be deferred; (2) A deferred donor who tests reactive for evidence of infection due to a communicable disease agent(s) listed in Sec. 610.40(a) may serve as a donor for blood or blood components shipped or used under Sec. 610.40(h)(2)(ii); (3) A deferred donor who showed evidence of infection due to hepatitis B surface antigen (HBsAg) when previously tested under Sec. 610.40(a), (b), and (e) subsequently may donate Source Plasma for use in the preparation of Hepatitis B Immune Globulin (Human) provided the current donation tests nonreactive for HBsAg and the donor is otherwise determined to be suitable; (4) A deferred donor, who otherwise is determined to be suitable for donation and tests reactive for anti-HBc or for evidence of infection due to HTLV, types I and II, may serve as a donor of Source Plasma; (5) A deferred donor who tests reactive for a communicable disease agent(s) described under Sec. 610.40(a) or reactive with a serological test for syphilis under Sec. 610.40(i), may serve as an autologous donor under Sec. 610.40(d). (b) A deferred donor subsequently may be found to be suitable as a donor of blood or blood components by a requalification method or process found acceptable for such purposes by FDA. Such a donor is considered no longer deferred. [66 FR 31164, June 11, 2001]